Boston Scientific Corporation (NYSE:BSX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Twenty-six analysts rate BSX an average of "Moderate Buy" (22 buys, 3 holds, 1 strong buy) with a 1‑year target of $93.91, though several brokerages have recently trimmed price targets.
• Near‑term headwinds: Multiple securities‑class‑action notices and a May 4 lead‑plaintiff deadline are creating legal overhang, and the CEO sold 160,901 shares (a ~10.23% reduction in his stake), adding to headline pressure.
• Recent results and guidance: Q1 beat marginally (EPS $0.80 vs. $0.79) with revenue up 11.6% to $5.20B; company set Q2 and FY2026 guidance (FY EPS 3.340–3.410) with analyst consensus around 3.38 EPS.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-six analysts that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $93.9130.

Several brokerages have issued reports on BSX. Argus raised Boston Scientific to a "strong-buy" rating in a report on Thursday, February 26th. Mizuho decreased their target price on Boston Scientific from $115.00 to $90.00 and set an "outperform" rating for the company in a research report on Monday, April 13th. Raymond James Financial restated an "outperform" rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Evercore cut their price target on Boston Scientific from $112.00 to $96.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. Finally, Canaccord Genuity Group reduced their price objective on Boston Scientific from $109.00 to $71.00 and set a "buy" rating for the company in a research note on Thursday, April 23rd.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Institutional interest: hedge fund Lone Pine (Stephen Mandel) recently opened a new position in BSX, signaling some large investors view recent weakness as a buying opportunity. Stephen Mandel Opens New Position
• Positive Sentiment: Analyst conviction persists in places: media pieces note that the average brokerage recommendation still favors adding BSX — analysts continue to highlight long‑term fundamentals despite recent headwinds. Wall Street Analysts Think Boston Scientific Is a Good Investment
• Neutral Sentiment: Investor attention and commentary: several outlets (Zacks, MSN, Yahoo) are amplifying debate about BSX’s outlook — this increases short‑term volatility but is informational rather than a direct catalyst. Zacks: Attracting Investor Attention
• Negative Sentiment: Mounting securities‑class‑action notices and lead‑plaintiff deadlines (May 4) from multiple law firms are creating legal risk and headline pressure; numerous firms are soliciting plaintiffs and investigating potential misstatements about market growth/competition. This is likely a near‑term overhang. PR Newswire: Opportunity to Lead Securities Fraud Lawsuit Faruqi & Faruqi Reminder
• Negative Sentiment: Analyst downgrades and price‑target cuts: several firms have trimmed targets (Argus cut its PT to $95; other outlets report an ~11% PT reduction to ~$90 and Daiwa moved BSX from strong‑buy to hold). Those revisions reflect the company’s recent guidance/earnings and rising competitive pressures and are weighing on sentiment. Argus Price Target Cut Price Target Reduced

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the business. FWL Investment Management LLC acquired a new position in Boston Scientific in the 2nd quarter valued at about $26,000. Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 170 shares during the period. Financial Consulate Inc. purchased a new position in shares of Boston Scientific in the 3rd quarter valued at approximately $25,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the 4th quarter valued at approximately $26,000. Finally, United Community Bank increased its holdings in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Down 1.7%

Shares of NYSE:BSX opened at $56.64 on Friday. The firm has a 50 day simple moving average of $67.06 and a 200-day simple moving average of $84.65. Boston Scientific has a twelve month low of $56.05 and a twelve month high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $84.18 billion, a PE ratio of 23.70, a P/E/G ratio of 1.04 and a beta of 0.62.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the firm posted $0.75 EPS. The company's revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts predict that Boston Scientific will post 3.38 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.